estimate_name,study_name,source_name,publication_date,source_type,estimate_grade,study_type,country,state,city,study_inclusion_criteria,study_exclusion_criteria,sampling_start_date,sampling_end_date,population_group,sex,age,age_min,age_max,subgroup_var,subgroup_specific_category,denominator_value,serum_pos_prevalence,seroprev_95_ci_lower,seroprev_95_ci_upper,dashboard_primary_estimate,test_adj,pop_adj,clustering_adjustment,academic_primary_estimate,sampling_method,test_name,test_manufacturer,test_type,specimen_type,isotypes,antibody_target,test_validation,sensitivity,specificity,overall_risk_of_bias,jbi_1,jbi_2,jbi_3,jbi_4,jbi_5,jbi_6,jbi_7,jbi_8,jbi_9,first_author,lead_institution,is_unity_aligned,url,date_created,last_modified_time,data_quality_status,zotero_citation_key,alpha_3_code
200801_Afghanistan_AfghanistanMinistryofPublicHealth,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020/8/1,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020/6/1,2020/6/15,Household and community samples,All,Multiple groups,5.0,,Primary Estimate,Overall national gen pop,9514,0.315,,,True,,True,,True,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021/5/19,2022/12/8,Verified,sayed_ataullah_prevalence_2020,AFG
200801_Afghanistan_AfghanistanMinistryofPublicHealthage5-17,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020/8/1,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020/6/1,2020/6/15,Household and community samples,All,Children and Youth (0-17 years),5.0,17.0,Age,age 5-17,4346,0.351,0.31,0.395,,,True,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021/6/10,2022/7/16,Verified,sayed_ataullah_prevalence_2020,AFG
200801_Afghanistan_AfghanistanMinistryofPublicHealthage18+,200801_Afghanistan_AfghanistanMinistryofPublicHealth,"Prevalence of COVID-19 and its Related Deaths in Afghanistan: A Nationwide, Population-Based Seroepidemiological Study July 202",2020/8/1,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"Blood samples are collected from two household member randomly (one from 5 to 17 years
and another from equal and above 18 years of age) ","Due to shortage of time and to have valid
data, insecure and inaccessible Enumerated Areas are not included in the study.",2020/6/1,2020/6/15,Household and community samples,All,Multiple groups,18.0,,Age,age 18+,5168,0.253,0.205,0.308,,,True,,,Stratified probability,Not reported/ Unable to specify,,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by manufacturers,,,['Moderate'],Yes,Yes,Yes,Yes,Yes,Unclear,Yes,No,Yes,Sayed Ataullah Saeedzai,Afghanistan Ministry of Public Health ,Not Unity-Aligned,https://moph.gov.af/sites/default/files/2020-08/Final%20COVID-19%20Survey%20English%20Report.pdf,2021/6/10,2022/7/16,Verified,sayed_ataullah_prevalence_2020,AFG
201220_Afghanistan_UnitedStatesAirForce,201220_Afghanistan_UnitedStatesAirForce,Using serosurveillance for SARS-CoV-2 to conserve PCR tests in a resource constrained combat environment,2020/12/31,Journal Article (Peer-Reviewed),National,Cross-sectional survey ,Afghanistan,,,"High risk populations included: those leaving quarantine, base defense guards, isolation unit guards, medical personnel, dining facility workers, and those who interact with local populations. ",,2020/4/17,2020/6/1,Essential non-healthcare workers,All,Adults (18-64 years),,,Primary Estimate,,1957,0.019,,,True,,,,True,Unclear,Not reported/ Unable to specify,,,,"['IgG', 'IgM']",,,,,['High'],Unclear,Unclear,Yes,No,Unclear,Unclear,Yes,No,Unclear,Brian White,United States Air Force,Not Unity-Aligned,http://dx.doi.org/10.1093/ofid/ofaa439.666,2021/5/2,2022/12/8,Verified,white_473_2020,AFG
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Overall,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,All,Multiple groups,18.0,70.0,Primary Estimate,,1527,0.7334999999999999,,,True,,,,True,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Age60+,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,All,Seniors (65+ years),60.0,70.0,Age,Age: ???60 years,530,0.8170000000000001,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_SexFemale,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,Female,Multiple groups,18.0,70.0,Sex/Gender,,1002,0.7525000000000001,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Age18-59,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,All,Adults (18-64 years),18.0,59.0,Age,Age: 18-59 years,996,0.6888,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Vaccinated,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,638,0.9013,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_Unvaccinated,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,All,Multiple groups,18.0,70.0,COVID-19 vaccination status,,889,0.613,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
220725_TiranaAndBerat_AcademyOfSciencesOfAlbania_SexMale,220725_TiranaAndBerat_AcademyOfSciencesOfAlbania,Estimating the seroprevalence of SARS-CoV-2 antibodies: Understanding population-level immunity in Albania at the end of the Alpha variant wave.,2022/7/25,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Albania,,"Tirana, Berat","""We measured the anti-S1 antibodies of the SARS-CoV-2 virus spike protein in a sample of urban population individuals aged 18 to 70 years, randomly selected from Tirana and Berat??s primary health centres?? electronic registers from June to July 2021.""",,2021/6/15,2021/7/15,Household and community samples,Male,Multiple groups,18.0,70.0,Sex/Gender,,525,0.6970999999999999,,,,,,,,Simplified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,,,,['Moderate'],Yes,Yes,Yes,Yes,No,Yes,Yes,Yes,Yes,Fabian Cenko,Academy of Sciences of Albania,Unity-Aligned,https://dx.doi.org/10.7189/jogh.12.03054,2022/8/11,2024/3/15,Verified,cenko_estimating_2022,ALB
230227_Albania_WorldHealthOrganization,230227_Albania_WorldHealthOrganization,Factors associated with receipt of COVID-19 vaccination and SARS-CoV-2 seropositivity among healthcare workers in Albania (February 2021-June 2022): secondary analysis of a prospective cohort study.,2023/2/27,Journal Article (Peer-Reviewed),Local,Prospective cohort,Albania,,,"""in early 2021, all employees at three publicly funded
hospitals in Albania (Durres, Fier, and Tirana) who were
eligible for vaccination were invited to participate in the
study, regardless of their intention to receive COVID-19
vaccine or known previous infections.""",,2021/2/19,2021/5/7,Health care workers and caregivers,All,Multiple groups,22.0,71.0,Primary Estimate,,1452,0.718,,,True,,,,True,Convenience,Wantai SARS-CoV-2 Total Ab ELISA,Beijing Wantai Biological,ELISA,Serum,"IgG, IgM, IgA",Spike,,,,['Moderate'],,No,Yes,Yes,,Yes,Yes,Yes,,Pernille Jorgensen,World Health Organization,Not Unity-Aligned,https://dx.doi.org/10.1016/j.lanepe.2023.100584,2023/5/3,2024/3/1,Unverified,jorgensen_factors_2023,ALB
230802_TiranaAndBeratCity_GeorgeMasonUniversity_2021_AntiS,230802_TiranaAndBeratCity_GeorgeMasonUniversity_2021,Dynamics of Anti-SARS-CoV-2 Antibodies in the Albanian Population: Impact of Infection and Vaccine-Induced Immunity during the COVID-19 Pandemic Year from August 2021 to August 2022,2023/8/2,Preprint,Local,Repeated cross-sectional study,Albania,,"Tirana, Berat City","Two independent samples from the Albanian general population, comprising all age groups, were studied in July-August of 2021 and 2022 to assess seroprevalence in the Albanian general population.",,2021/7/15,2021/8/15,Multiple populations,All,Multiple groups,4.0,97.0,Primary Estimate,Anti-S,1716,0.7179,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['High'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,George Mason University,Not Unity-Aligned,https://doi.org/10.20944/preprints202308.0151.v1,2023/9/22,2024/3/1,Unverified,sulcebe_dynamics_2023,ALB
230802_TiranaAndBeratCity_GeorgeMasonUniversity_2022_AntiS,230802_TiranaAndBeratCity_GeorgeMasonUniversity_2022,Dynamics of Anti-SARS-CoV-2 Antibodies in the Albanian Population: Impact of Infection and Vaccine-Induced Immunity during the COVID-19 Pandemic Year from August 2021 to August 2022,2023/8/2,Preprint,Local,Repeated cross-sectional study,Albania,,"Tirana, Berat City","Two independent samples from the Albanian general population, comprising all age groups, were studied in July-August of 2021 and 2022 to assess seroprevalence in the Albanian general population.",,2022/7/15,2022/8/15,Multiple populations,All,Multiple groups,1.0,87.0,Primary Estimate,Anti-S,1899,0.9115,,,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['High'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,George Mason University,Not Unity-Aligned,https://doi.org/10.20944/preprints202308.0151.v1,2023/9/22,2024/3/1,Unverified,sulcebe_dynamics_2023,ALB
230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Dec,230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Dec,Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population.,2023/8/26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Albania,,Tirana,"This study aims to fill this gap by providing data on the changes in COVID-19 seroprevalence among the adult urban population of Albania between July and December 2020, using two independent, randomly selected samples of individuals aged 20??70 years who reside in Metropolitan Tirana, which represents approximately one-third of Albania??s urban population [9].",,2020/12/21,2020/12/28,Household and community samples,All,Adults (18-64 years),20.0,70.0,Primary Estimate,"Round 2 (Dec 21 - Dec 28, 2020)",815,0.482,0.448,0.517,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['Moderate'],,Yes,Yes,Yes,,Yes,Yes,Yes,,Genc Sulcebe,"Catholic University ""Our Lady of Good Counsel""",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e19547,2023/10/10,2024/4/24,Verified,sulcebe_rapid_2023,ALB
230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Jul,230826_Tirana_CatholicUniversityOurLadyOfGoodCounsel_Jul,Rapid increase of SARS-CoV-2 seroprevalence during the second half of the COVID-19 pandemic year 2020 in the adult urban Albanian population.,2023/8/26,Journal Article (Peer-Reviewed),Local,Repeated cross-sectional study,Albania,,Tirana,"This study aims to fill this gap by providing data on the changes in COVID-19 seroprevalence among the adult urban population of Albania between July and December 2020, using two independent, randomly selected samples of individuals aged 20??70 years who reside in Metropolitan Tirana, which represents approximately one-third of Albania??s urban population [9].",,2020/6/27,2020/7/3,Household and community samples,All,Adults (18-64 years),20.0,70.0,Primary Estimate,"Round 1 (June 27 - July 3, 2020)",266,0.075,0.043,0.107,True,,,,True,Stratified probability,Anti-SARS-CoV-2 ELISA IgG,EUROIMMUN,ELISA,Serum,IgG,Spike,Validated by manufacturers,0.944,0.996,['Moderate'],Yes,Yes,No,Yes,Unclear,Yes,Yes,Yes,Yes,Genc Sulcebe,"Catholic University ""Our Lady of Good Counsel""",Unity-Aligned,https://dx.doi.org/10.1016/j.heliyon.2023.e19547,2023/10/10,2024/4/24,Verified,sulcebe_rapid_2023,ALB
230607_Oran_UniversityofOran_Overall,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Primary Estimate,,1185,0.356,0.3294,0.3838,True,,,,True,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EsSenia,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Es Senia,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Es Senia,77,0.247,0.164,0.3535,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Benfreha,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Benfreha,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Benfreha,21,0.857,0.6537,0.9502,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiMefsoukh,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Mefsoukh,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Mefsoukh,12,0.75,0.4677,0.9111,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age70-79,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,65,0.4,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_MersEIKebir,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Mers EI Kebir,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Mers EI Kebir,12,0.5,0.2538,0.7462,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age10-19,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,19-10ÔÂ,217,0.2765,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Misserghin,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Misserghin,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Misserghin,23,0.174,0.0698,0.3714,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Tafraoui,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Tafraoui,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Tafraoui,10,0.1,0.0179,0.4041,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_MersEIHedjaj,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Mers EI Hedjaj,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Mers EI Hedjaj,12,0.917,0.6461,0.9851,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_SidiChahmi,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Sidi Chahmi,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Sidi Chahmi,118,0.331,0.2522,0.4195,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIKerma,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Kerma,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,EI Kerma,26,0.0,0.0,0.1287,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Bousfer,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bousfer,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Bousfer,17,0.353,0.1731,0.587,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_OuedTlelat,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Oued Tlelat,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Oued Tlelat,15,0.333,0.1518,0.5829,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEITurk,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Turk,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Turk,29,0.448,0.2841,0.6245,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEIBia,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Bia,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Bia,24,0.708,0.5083,0.8508,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_SidiBenyebkra,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Sidi Benyebkra,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Sidi Benyebkra,6,0.833,0.4365,0.9699,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiBenOkba,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Ben Okba,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Ben Okba,12,0.5,0.2538,0.7462,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age50-59,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,183,0.3825,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIOngor,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Ongor,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,EI Ongor,10,0.3,0.1078,0.6032,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_EIBraya,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",EI Braya,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,EI Braya,6,0.333,0.0968,0.7,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age40-49,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,189,0.381,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Gdyel,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Gdyel,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Gdyel,30,0.733,0.5555,0.8582,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Arzew,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Arzew,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Arzew,64,0.672,0.55,0.7743,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age20-29,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,119,0.3361,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age30-39,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,162,0.3827,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Oran,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Oran,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Oran,308,0.338,0.2871,0.3922,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age80+,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Seniors (65+ years),80.0,,Age,80+,35,0.3143,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Boufatis,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Boufatis,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Boufatis,8,0.75,0.4093,0.9285,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_BirEIDjir,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bir EI Djir,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Bir EI Djir,257,0.105,0.0732,0.1485,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_AinEIKerma,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Ain EI Kerma,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Ain EI Kerma,5,0.0,0.0,0.4345,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999998,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Boutlelis,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Boutlelis,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Boutlelis,19,0.263,0.1181,0.4879,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_HassiBounif,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Hassi Bounif,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Hassi Bounif,53,0.774,0.6447,0.8654,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Bethioua,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Algeria,"Oran
",Bethioua,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,,,Geographical area,Bethioua,11,0.909,0.6227,0.9838,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.905,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2023/6/29,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age<10,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Children and Youth (0-17 years),,9.0,Age,<10,86,0.3488,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
230607_Oran_UniversityofOran_Age60-69,230607_Oran_UniversityofOran,Seroprevalence of COVID-19 in Oran: Cross-Sectional Study,2023/6/7,Journal Article (Peer-Reviewed),Regional,Cross-sectional survey ,Algeria,"Oran
",,"""included all 26 municipalities of Oran Province. The study specifically targeted household members and was conducted from 7 January to 20 January 2021""","""two forms had a significant amount of missing data, leading to their exclusion from the analysis""",2021/1/7,2021/1/20,Household and community samples,All,Multiple groups,60.0,69.0,Age,60-69,129,0.3953,,,,,,,,Stratified probability,COVID-19 IgG/IgM Rapid Test,Zhejiang Orient Gene Biotech,LFIA,Multiple Types,"['IgG', 'IgM']",Spike,Validated by manufacturers,0.9049999999999996,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Abdessamad Dali-Ali,University of Oran,Unity-Aligned,https://dx.doi.org/10.1128/spectrum.00876-23,2024/4/30,2024/4/30,Verified,dali-ali_seroprevalence_2023,DZA
210521_Andorra_ISGlobal_Overall,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Multiple groups,2.0,,Primary Estimate,overall,72964,0.11,,,True,,,,True,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_40-49,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Adults (18-64 years),40.0,49.0,Age,40-49,10985,0.1169999999999999,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_80-89,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Seniors (65+ years),80.0,89.0,Age,80-89,1093,0.148,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_Female,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,Female,Multiple groups,2.0,,Sex/Gender,female,27858,0.125,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_70-79,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Seniors (65+ years),70.0,79.0,Age,70-79,2776,0.1369999999999999,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_60-69,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Adults (18-64 years),60.0,69.0,Age,60-69,5655,0.136,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_2-9,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Children and Youth (0-17 years),2.0,9.0,Age,0-9,3899,0.115,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_90+,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Seniors (65+ years),90.0,,Age,90+,226,0.173,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_50-59,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Adults (18-64 years),50.0,59.0,Age,50-59,9560,0.146,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_Male,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,Male,Multiple groups,2.0,,Sex/Gender,male,28301,0.124,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_20-29,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Adults (18-64 years),20.0,29.0,Age,20-29,6305,0.107,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_30-39,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Adults (18-64 years),30.0,39.0,Age,30-39,8587,0.105,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210521_Andorra_ISGlobal_10-19,210521_Andorra_ISGlobal,"Mass SARS-CoV-2 serological screening, a population-based study in the Principality of Andorra",2021/5/21,Journal Article (Peer-Reviewed),National,Repeated cross-sectional study,Andorra,,,"We conducted a two-phase screening study on the entire popula-tion in Andorra above the age of 2 who voluntarily signed theinformed consent. Beyond Andorran citizens, we also included regis-tered cross-border workers.", The only exclusion criterion was therefusal to provide the signed informed consent,2020/5/4,2020/5/28,Household and community samples,All,Children and Youth (0-17 years),10.0,19.0,Age,19-10ÔÂ,6196,0.143,,,,,,,,Entire sample,2019-nCoV IgG/IgM Antibody Detection Kit,Zhuhai Livzon Diagnostics Inc,LFIA,Whole Blood,"['IgG', 'IgM']",,Validated by independent authors/third party/non-developers,0.92,1.0,['Moderate'],Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Yes,Cristina Royo Cebrecos,ISGlobal,Unity-Aligned,https://www.sciencedirect.com/science/article/pii/S266677622100096X,2021/7/29,2024/3/1,Verified,royo-cebrecos_mass_2021,AND
210921_Andorra_HospitalNostraSenyoradeMeritxell_November,210921_Andorra_HospitalNostraSenyoradeMeritxell_November,1601P SARS-CoV-2 serological response in cancer patients in the Principality of Andorra (COVONCO study),2021/9/21,Presentation or Conference,Local,Prospective cohort,Andorra,,,All adult patients with cancer diagnosis within 5 years (2016-April 2020) who accepted participation were included since May 2020.,,2020/11/1,2020/11/30,Patients seeking care for non-COVID-19 reasons,All,Adults (18-64 years),,,Primary Estimate,,156,0.0641,,,True,,,,True,Convenience,Not reported/ Unable to specify,,,,,,,,,['High'],,No,No,No,,Unclear,Yes,No,,C Royo-Cebrecos,Hospital Nostra Senyora de Meritxell,Not Unity-Aligned,http://dx.doi.org/10.1016/j.annonc.2021.08.1594,2021/9/28,2022/7/16,Unverified,royo-cebrecos_1601p_2021,AND
220412_Andorra_HospitalNostraSenyoradeMeritxell_Primary,220412_Andorra_HospitalNostraSenyoradeMeritxell,Seroprevalence study prior and post vaccination in Cancer patients in Principality of Andorra (COVONCO study),2022/4/12,Preprint,National,Cross-sectional survey ,Andorra,,,"This study included all patients ??? 18 years of age with a
diagnosis of solid tumour or haematological malignancy in the last 5 years (from January 2016-May 2020) who participated in the nation-wide SARS-CoV-2 population screening in May 202015 with means
of serological testing and who provided informed oral consent","Patients who failed to provide informed oral consent, had been cancer-free for the last 5 years or deceased before the start of the study from a
non-COVID-19 related death were excluded. Anonymized use of data was collected as per standard of care.",2020/5/15,2021/6/15,Representative patient population,All,Multiple groups,18.0,,Primary Estimate,overall seroprevalence ,373,0.182,,,True,,,,True,Convenience,"2019-nCoV IgG/IgM Antibody Detection Kit,Elecsys?? Anti??SARS??CoV??2 (S),Elecsys?? Anti??SARS??CoV??2 (N)","Zhuhai Livzon Diagnostics Inc,Roche Diagnostics",Multiple Types,Plasma,"['IgA', 'IgG', 'IgM']","['Nucleocapsid(N-protein)', 'Spike']",Multiple tests with diff validations or values derived from each type,,,['High'],,No,No,Yes,,Unclear,Yes,No,,Cristina Royo-Cebrecos,Hospital Nostra Senyora de Meritxell,Not Unity-Aligned,10.21203/rs.3.rs-1538781/v1,2022/4/21,2024/3/1,Unverified,royo-cebrecos_mass_2021_1,AND
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,12.0,67.0,Primary Estimate,Overall,660,0.011,,,True,,,,True,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/5/30,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_UrbanArea,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,335,0.015,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_<40,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Adults (18-64 years),12.0,39.0,Age,,331,0.009,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_Luanda,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,659,0.011,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_Outside Luanda,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,1,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_Male,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,Male,Multiple groups,12.0,67.0,Sex/Gender,Male,572,0.012,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_Female,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,Female,Multiple groups,12.0,67.0,Sex/Gender,Female,88,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_RuralArea,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,12.0,67.0,Geographical area,,352,0.006,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de_IgG_40+,210506_Luanda_InstitutoNacionaldeInvestiga????oemSa??de,"Serological identification of past and recent SARS-CoV-2 infection through antibody screening in Luanda, Angola.",2021/5/6,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Angola,Luanda Province,Luanda,"Individuals seeking health services at Instituto Nacional de Investiga????o em Sa??de (INIS), located in Luanda, the capital city of Angola",,2020/7/15,2020/9/15,Residual sera,All,Multiple groups,40.0,67.0,Age,,329,0.012,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,Other,Serum,"['IgG', 'IgM']",,,,,['High'],No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Unclear,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Not Unity-Aligned,https://dx.doi.org/10.1002/hsr2.280,2021/7/22,2024/3/1,Verified,sebastiao_serological_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Primary,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,Luanda,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,All,Adults (18-64 years),18.0,61.0,Primary Estimate,,343,0.047,,,True,,,,True,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_20-40,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,All,Adults (18-64 years),20.0,40.0,Age,20-40 years-old,279,0.047,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Feb2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020/2/1,2020/2/29,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,February 2020 ,42,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Sep2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020/9/1,2020/9/30,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,September 2020 ,55,0.2,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Dec2019,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/1,2019/12/31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,December 2019 ,25,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Aug2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020/8/1,2020/8/31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,August 2020 ,24,0.125,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Female,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,Female,Adults (18-64 years),18.0,61.0,Sex/Gender,,24,0.0,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Jul2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020/7/1,2020/7/31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,July 2020 ,52,0.019,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Jan2020,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2020/1/1,2020/1/31,Blood donors,All,Adults (18-64 years),18.0,61.0,Time frame,January 2020 ,145,0.007,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_<20,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,All,Adults (18-64 years),18.0,19.0,Age,<20 years-old,7,0.143,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_Male,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,Male,Adults (18-64 years),18.0,61.0,Sex/Gender,,319,0.05,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
211102_Luanda_UniversidadeAgostinhoNeto_>40,211102_Luanda_UniversidadeAgostinhoNeto,"Seroprevalence of anti-SARS-CoV-2 antibodies and risk factors among healthy blood donors in Luanda, Angola.",2021/11/2,Journal Article (Peer-Reviewed),Local,Retrospective cohort,Angola,,Luanda,"Included subjects who were apparently healthy for donation at the Instituto Nacional de Sangue and Cl??nica Girassol, both in Luanda, the capital city of Angola, between December 2019 to February 2020 and between July to September 2020","NR
",2019/12/15,2020/9/15,Blood donors,All,Adults (18-64 years),41.0,61.0,Age,>40 years-old,57,0.035,,,,,,,,Convenience,VIDAS Multiparametric immunoassay system for medium throughput,Biomerieux,ELISA,Plasma,"['IgG', 'IgM']",,,,,['High'],No,No,No,Yes,No,Yes,Yes,Yes,,Cruz Sebastiao,Instituto Nacional de Investiga????o em Sa??de,Unity-Aligned,https://dx.doi.org/10.1186/s12879-021-06814-0,2021/11/10,2024/3/1,Verified,sebastiao_seroprevalence_2021,AGO
"200718_BuenosAires_MinisterofHealth,BuenosAiresCity_Homeless",200718_BuenosAires_MinisterofHealthBuenosAiresCity_2_Homeless,"Community-level SARS-CoV-2 Seroprevalence Survey in urban slum dwellers of Buenos Aires City, Argentina: a participatory research.",2020/7/18,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,"A sample for convenience of 60 homeless people in the ??Comedor del Fondo??, a popular dining room managed by a non-governmental organization. This sample is not part of the overall prevalence estimate, it was done as a first step. ",,2020/6/10,2020/7/1,Persons experiencing homelessness,All,Multiple groups,14.0,,Primary Estimate,,60,0.36,,,True,,,,True,Convenience,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Multiple Types,IgG,Spike,Validated by independent authors/third party/non-developers,0.95,1.0,['High'],Yes,No,No,No,Unclear,Unclear,Yes,Yes,,Silvana Figar,"Minister of Health, Buenos Aires City",Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.07.14.20153858v1,2020/7/17,2022/7/16,Verified,figar_community-level_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_overall,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020/8/28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020/7/15,2020/7/16,Household and community samples,All,Multiple groups,20.0,,Primary Estimate,,284,0.148,0.111,0.195,True,,,,True,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.95,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021/4/21,2022/7/16,Verified,munoz_surveillance_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_male,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020/8/28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020/7/15,2020/7/16,Household and community samples,Male,Multiple groups,20.0,,Sex/Gender,male,110,0.127,0.077,0.204,,,,,,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.95,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021/4/21,2022/7/16,Verified,munoz_surveillance_2020,ARG
200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires_female,200828_VillaAzul_MinisterioDeSaludDeLaProvinciaDeBuenosAires,"Surveillance and Seroprevalence: Evaluation of IgG antibodies for SARS-Cov2 by ELISA in the popular neighborhood Villa Azul, Quilmes, province of Buenos Aires, Argentina",2020/8/28,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Quilmes,Residents of Villa Azul who were over 19 years of age,,2020/7/15,2020/7/16,Household and community samples,Female,Multiple groups,20.0,,Sex/Gender,female,173,0.162,0.114,0.225,,,,,,Stratified non-probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,Validated by manufacturers,0.95,1.0,['High'],Yes,No,No,Yes,Yes,Unclear,Yes,Yes,Yes,Laura Munoz,Ministerio de Salud de la Provincia de Buenos Aires,Unity-Aligned,https://preprints.scielo.org/index.php/scielo/preprint/view/1147,2021/4/21,2022/7/16,Verified,munoz_surveillance_2020,ARG
200909_BuenosAires_InstitutoNacionalDeEpidemiologia_Overall,200909_BuenosAires_InstitutoNacionalDeEpidemiologia,"Seroprevalence of the SARS-CoV-2 infection in health workers of the Sanitary Region VIII, at province of Buenos Aires",2020/9/9,Preprint,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,HCWs from public facilities from the RS VIII from Buenos Aires province during June 2020. ,,2020/6/3,2020/7/6,Health care workers and caregivers,All,Multiple groups,19.0,73.0,Primary Estimate,,738,0.0075,0.0,0.0813,True,,True,,True,Stratified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Plasma,"['IgG', 'IgM']",Spike,,,,['Moderate'],Yes,Yes,Yes,No,Yes,Unclear,Yes,No,Yes,Andrea Silva,Instituto Nacional de Epidemiologia,Not Unity-Aligned,https://www.medrxiv.org/content/10.1101/2020.09.07.20189050v1,2020/11/10,2022/7/16,Verified,silva_seroprevalence_2020,ARG
201201_BuenosAires_HospitalGeneraldeNi??osPedrodeElizalde_overall,201201_BuenosAires_HospitalGeneraldeNi??osPedrodeElizalde,Seroprevalence of SARS-CoV-2 antibodies among physicians from a children's hospital,2020/12/1,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Province of Buenos Aires,Autonomous City of Buenos Aires,"Staff physicians and residents from Hospital General de Ni??os Pedro de Elizalde (HGNPE) who worked at the hospital by April 30th, 2020",,2020/6/8,2020/6/9,Health care workers and caregivers,All,Adults (18-64 years),,,Primary Estimate,Physicians and residents overall,116,0.009,0.001,0.055,True,,,,True,Simplified probability,MAGLUMI 2019-nCoV IgM/IgG,Snibe Co. Ltd (Shenzhen New Industries Biomedical Engineering Co. Ltd),CLIA,Serum,"['IgG', 'IgM']",,Validated by manufacturers,0.956,0.96,['High'],Yes,Yes,No,No,Unclear,Yes,Yes,No,Unclear,Claudia Insua,Hospital General de Ni??os Pedro de Elizalde,Not Unity-Aligned,https://dx.doi.org/10.5546/aap.2020.eng.381,2021/1/25,2024/3/1,Verified,insua_seroprevalence_2020,ARG
201230_ArgentinaHurlingham_UniversidadNacionalHurlingham,201230_Hurlingham_UniversidadNacionalHurlingham,Se presentaron los resultados del estudio de seroprevalencia de COVID-19 que realiz?? la Universidad en el Municipio de Hurlingham,2020/12/30,Institutional Report,Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,The tests were carried out using a drop of blood taken from people's homes,,2020/12/1,2020/12/30,Household and community samples,All,Multiple groups,18.0,90.0,Primary Estimate,,1182,0.121,0.1,0.142,True,,,,True,Stratified probability,SEROKIT-ELISA COVIDAR IgG,COVIDAR,ELISA,Serum,IgG,,,,,['Moderate'],Yes,Yes,Yes,No,Unclear,Unclear,Yes,No,Unclear,Universidad Nacional De Hurlingham,Universidad Nacional De Hurlingham,Not Unity-Aligned,http://www.unahur.edu.ar/es/se-presentaron-los-resultados-del-estudio-de-seroprevalencia-de-covid-19-que-realizo-la-universidad,2021/5/21,2022/7/16,Verified,universidad_nacional_de_hurlingham_se_2020,ARG
210107_BuenosAires_UniversityOfBuenosAires_Primary,210107_BuenosAires_UniversityOfBuenosAires,Assesment of SARS-CoV-2 infection-in dentists and supporting staff at a university dental hospital in Argentina,2021/1/7,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,,Buenos Aires,"The sample consisted of 358 FOUBA workers from clinical and nonclinical areas, male and female, over 21 years old, who provided essential services during the first 180 days of the COVID-19 pandemic during the PMSIs.",,2020/3/1,2020/10/31,Health care workers and caregivers,All,Adults (18-64 years),21.0,59.0,Primary Estimate,ELISA test,317,0.03,0.02,0.05,True,,,,True,Stratified non-probability,Not reported/ Unable to specify,,ELISA,,,,Validated by manufacturers,0.85,0.95,['High'],Yes,No,No,Yes,Unclear,Unclear,Yes,No,Yes,Puia Sebastian ,University of Buenos Aires,Not Unity-Aligned,https://dx.doi.org/10.1016/j.jobcr.2021.01.006,2021/2/18,2022/7/16,Verified,sebastian_assesment_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021/1/21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020/6/10,2020/6/26,Persons living in slums,All,Multiple groups,14.0,,Primary Estimate,,873,0.534,0.528,0.541,True,,True,,True,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021/4/21,2022/7/16,Verified,figar_severe_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires_male,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021/1/21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020/6/10,2020/6/26,Persons living in slums,Male,Multiple groups,14.0,,Sex/Gender,male,374,0.515,0.506,0.524,,,True,,,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021/4/21,2022/7/16,Verified,figar_severe_2021,ARG
210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires_Female,210121_BarrioMugica_MinistryOfHealthOfTheCityOfBuenosAires,SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 SEROEPIDEMIOLOGY STUDY IN ARGENTINIAN SLUM ,2021/1/21,Journal Article (Peer-Reviewed),Local,Cross-sectional survey ,Argentina,Buenos Aires,Buenos Aires,Men and women 14 years of age or older who are inhabitants of Barrio Murgica in Buenos Aires City,,2020/6/10,2020/6/26,Persons living in slums,Female,Multiple groups,14.0,,Sex/Gender,female,499,0.5529999999999999,0.544,0.562,,,True,,,Simplified probability,COVIDAR IgM and IgG ELISA,CONICET,ELISA,Serum,IgG,Spike,Validated by independent authors/third party/non-developers,0.9,1.0,['Low'],Yes,Yes,Yes,Yes,No,Unclear,Yes,Yes,Yes,Silvana Figar,Ministry of Health of the City of Buenos Aires,Unity-Aligned,https://www.medicinabuenosaires.com/revistas/vol81-21/destacado/original_7453.pdf,2021/4/21,2022/7/16,Verified,figar_severe_2021,ARG
210122_BuenosAires_GovernmentOfTheProvinceOfBuenosAires,210122_BuenosAiresCity_GovernmentOfTheProvinceOfBuenosAires,"ONLY 13 PERCENT OF THE
  NEIGHBOURS OF 30 PEOPLE'S NEIGHBOURHOODS OF THE AMBA HAD CORONAVIRUS",2021/1/22,News and Media,Local,Cross-sectional survey ,Argentina,Buenos Aires,Metropolitan Area of Buenos Aires,,,2020/7/15,2020/12/15,Household and community samples,All,Multiple groups,,,Primary Estimate,,9000,0.13,,,True,,,,True,Unclear,Not reported/ Unable to specify,,ELISA,Whole Blood,,,,,,['High'],,Unclear,Yes,No,,Unclear,Yes,No,,Government of the Province of Buenos Aires,Government of the Province of Buenos Aires,Not Unity-Aligned,https://www.gba.gob.ar/saludprovincia/noticias/s%C3%B3lo_el_13_por_ciento_de_los_vecinos_y_vecinas_de_30_barrios_populares_del,2021/5/17,2022/7/16,Unverified,government_of_the_province_of_buenos_aires_only_2021,ARG
